The dynamic relationship between mu and kappa opioid receptors in body temperature regulation.
Level 5 - mechanism / opinion, no new human data
Animal laboratory experiment
PubMed 16257420 · doi:10.1016/j.lfs.2005.04.084
What was done
Researchers evaluated the interaction between central mu and kappa opioid receptors in thermoregulation in unrestrained rats. Animals received intracerebroventricular (icv) microinjections of the selective kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI; 1.25 nmol or 25 nmol) and the selective mu opioid receptor antagonist CTAP (1.25, 5, or 10 nmol), administered either alone or sequentially (CTAP given 15 minutes after nor-BNI, or nor-BNI given before CTAP). Changes in body temperature were tracked via rectal measurements.
What was found
Low-dose nor-BNI (1.25 nmol icv) alone did not alter body temperature, but a high dose (25 nmol icv) produced an increase in body temperature. CTAP (1.25 nmol icv) significantly antagonized the nor-BNI-induced temperature elevation. Additionally, CTAP alone at 5 or 10 nmol significantly reduced body temperature, an effect that was blocked by pre-treatment with 1.25 nmol nor-BNI. The abstract reported directions and statistical significance but did not provide exact numerical values, standard deviations, or effect sizes.
Why it matters
This work demonstrates a tonic homeostatic balance between mu and kappa opioid receptor systems in baseline body temperature regulation. It highlights that blocking one opioid receptor subtype can unmask the physiological effects mediated by the other.
Limits
The study was conducted entirely in rats using direct intracerebroventricular drug delivery, limiting direct clinical translation to humans and systemic routes of administration. The abstract omitted specific sample sizes, baseline temperatures, quantitative effect sizes, and precise statistical values.
Cited by
- supports Dynorphin is part of the thermoregulatory pathway and acts to cool the body down when body temperature rises.